Related Experiment Video
Updated: Jun 15, 2026

Experimental Infection of Mice with the Parasitic Nematode Strongyloides ratti
Published on: January 17, 2025
Minimal change nephrotic syndrome in a patient with strongyloidiasis
Mieko Miyazaki1, Masahito Tamura, Narutoshi Kabashima
1Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Abstract:
Strongyloidiasis, a chronic infection caused by the intestinal parasite Strongyloides stercoralis, is prevalent in the Nansei Islands of Japan. Here, we report our findings on a case of strongyloidiasis complicated with steroid-resistant minimal change nephrotic syndrome in a 69-year-old male resident of Fukuoka Prefecture who had lived in Yakushima, one of the Nansei Islands, until age 15. In October 2006, he developed proteinuria and edema, and was diagnosed with minimal change nephrotic syndrome on the basis of the renal biopsy findings. Following treatment with prednisolone, the level of proteinuria decreased to 0.29 g/day by day 35. However, 5 days later (day 40), the patient developed persistent watery diarrhea and vomiting, leading to dehydration and malnutrition. Pneumonia and bacterial meningitis subsequently developed (day 146); filarial (infectious-type) and rhabditiform (noninfectious-type) S. stercoralis larvae were detected for the first time in the patient's sputum, gastric juice, feces, and urine. Although treatment with ivermectin was started immediately and the parasitosis responded to the treatment, the patient died of sepsis. Consequently, although strongyloidiasis is a rare infection except in endemic regions, it is essential to consider the possibility of this disease and begin treatment early for patients who have lived in endemic areas and who complain of unexplained diarrhea during steroid-induced or other immunosuppression.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome I : Introduction
Giardiasis
Chronic Kidney Disease II: Clinical Manifestations
Anthelminthic Agents
